{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:20:00Z","timestamp":1783488000711,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373661"],"award-info":[{"award-number":["82373661"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81773515"],"award-info":[{"award-number":["81773515"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82103930"],"award-info":[{"award-number":["82103930"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong","doi-asserted-by":"crossref","award":["2022A1515011546"],"award-info":[{"award-number":["2022A1515011546"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Epidemiol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The Guangzhou Breast Cancer Study (GBCS) is a patient-based prospective cohort study designed to identify risk factors and underlying mechanisms for breast cancer (BC) incidence and prognosis, specifically addressing the need for individualized prevention in South China, where BC incidence is notably high. Based in Guangzhou, China, the GBCS began recruitment in 2008, comprises three complementary studies: the Guangzhou breast cancer cohort with 5471 breast cancer patients, a case\u2013control study with 1551 cases and 1605 controls, and an immunohistochemistry (IHC) cohort with 1063 breast cancer patients. Participants are primarily aged 41\u201360\u00a0years. Cohort follow-up is conducted every three months in the first year, every six months in the second and third years, and annually thereafter. High follow-up rates have been achieved until 2023, with 73.5% for the Guangzhou breast cancer cohort and 98.6% for the IHC cohort still active. Baseline data collection included demographic characteristics and breast cancer risk factors, while follow-up data included survival, treatment details, disease history, occupational history, post-diagnostic lifestyle, and laboratory measures, including genetic markers, proteins, and environmental exposures. The study encourages global collaborations and invites interested researchers to contact the corresponding author at xulin27@ mail.sysu.edu.cn with specific research ideas or proposals.<\/jats:p>","DOI":"10.1007\/s10654-024-01180-y","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T14:24:58Z","timestamp":1734359098000},"page":"1401-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cohort profile: Guangzhou breast cancer study (GBCS)"],"prefix":"10.1007","volume":"39","author":[{"given":"Jiao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Kun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu Shu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze Fang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0537-922X","authenticated-orcid":false,"given":"Lin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"crossref","unstructured":"Collaboration GBoDC. The Global Burden of Cancer 2013. JAMA Oncology 2015; 1: 505\u201327.","DOI":"10.1001\/jamaoncol.2015.0735"},{"key":"1180_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/s41597-023-02253-5","volume":"10","author":"Y Xu","year":"2023","unstructured":"Xu Y, Gong M, Wang Y, Yang Y, Liu S, Zeng Q. Global trends and forecasts of breast cancer incidence and deaths. Sci Data. 2023;10:334.","journal-title":"Sci Data"},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323.","journal-title":"Breast"},{"key":"1180_CR4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1180_CR5","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1016\/S1470-2045(13)70567-9","volume":"15","author":"L Fan","year":"2014","unstructured":"Fan L, Strasser-Weippl K, Li J-J, et al. Breast cancer in China. Lancet Oncol. 2014;15:e279\u201389.","journal-title":"Lancet Oncol"},{"key":"1180_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Nat Cancer Center. 2024;4:47\u201353.","journal-title":"J Nat Cancer Center"},{"key":"1180_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2217\/14796694.2.2.257","volume":"2","author":"AC Antoniou","year":"2006","unstructured":"Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. Future Oncol. 2006;2:257\u201374.","journal-title":"Future Oncol"},{"key":"1180_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-008-0070-x","volume":"115","author":"CE Jacobi","year":"2009","unstructured":"Jacobi CE, de Bock GH, Siegerink B, van Asperen CJ. Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat. 2009;115:381\u201390.","journal-title":"Breast Cancer Res Treat"},{"key":"1180_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2023.102326","volume":"64","author":"A Shen","year":"2023","unstructured":"Shen A, Wei X, Zhu F, et al. Risk prediction models for breast cancer-related lymphedema: A systematic review and meta-analysis. Eur J Oncol Nurs. 2023;64: 102326.","journal-title":"Eur J Oncol Nurs"},{"key":"1180_CR10","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.envres.2011.11.005","volume":"112","author":"LJ Chen","year":"2012","unstructured":"Chen LJ, Tang LY, He JR, et al. Urinary strontium and the risk of breast cancer: a case-control study in Guangzhou. China Environ Res. 2012;112:212\u20137.","journal-title":"China Environ Res"},{"key":"1180_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.sleep.2014.11.017","volume":"16","author":"P Wang","year":"2015","unstructured":"Wang P, Ren FM, Lin Y, et al. Night-shift work, sleep duration, daytime napping, and breast cancer risk. Sleep Med. 2015;16:462\u20138.","journal-title":"Sleep Med"},{"key":"1180_CR12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/mc.22493","volume":"56","author":"W Lin","year":"2017","unstructured":"Lin W, Lin HD, Guo XY, et al. Allelic expression imbalance polymorphisms in susceptibility chromosome regions and the risk and survival of breast cancer. Mol Carcinog. 2017;56:300\u201311.","journal-title":"Mol Carcinog"},{"key":"1180_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.33176\/AACB-19-00024","volume":"40","author":"SC Wilschefski","year":"2019","unstructured":"Wilschefski SC, Baxter MR. Inductively coupled plasma mass spectrometry: introduction to analytical aspects. Clin Biochem Rev. 2019;40:115\u201334.","journal-title":"Clin Biochem Rev"},{"key":"1180_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2988","volume":"19","author":"Y-H Liao","year":"2017","unstructured":"Liao Y-H, Ren J-T, Zhang W, et al. Polymorphisms in homologous recombination repair genes and the risk and survival of breast cancer. J Gene Med. 2017;19: e2988.","journal-title":"J Gene Med"},{"key":"1180_CR15","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-6442-0_5","volume-title":"Genotyping: methods and protocols","author":"JA Ellis","year":"2017","unstructured":"Ellis JA, Ong B. The MassARRAY\u00ae system for targeted SNP genotyping. In: White SJ, Cantsilieris S, editors. Genotyping: methods and protocols. New York: Springer; 2017. p. 77\u201394."},{"key":"1180_CR16","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s10549-021-06125-7","volume":"187","author":"QX Chen","year":"2021","unstructured":"Chen QX, Yang YZ, Liang ZZ, et al. Time-varying effects of FOXA1 on breast cancer prognosis. Breast Cancer Res Treat. 2021;187:867\u201375.","journal-title":"Breast Cancer Res Treat"},{"key":"1180_CR17","first-page":"531","volume":"111","author":"MH Ng","year":"1998","unstructured":"Ng MH, Chen HL, Luo RX, et al. Serological diagnosis of nasopharyngeal carcinoma by enzyme linked immunosorbent assay: optimization, standardization and diagnostic criteria. Chin Med J. 1998;111:531\u20136.","journal-title":"Chin Med J"},{"key":"1180_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.canlet.2011.05.012","volume":"309","author":"JR He","year":"2011","unstructured":"He JR, Tang LY, Yu DD, et al. Epstein\u2013Barr virus and breast cancer: serological study in a high-incidence area of nasopharyngeal carcinoma. Cancer Lett. 2011;309:128\u201336.","journal-title":"Cancer Lett"},{"key":"1180_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13071-015-0778-5","volume":"8","author":"L Wang","year":"2015","unstructured":"Wang L, He LY, Meng DD, et al. Seroprevalence and genetic characterization of Toxoplasma gondii in cancer patients in Anhui Province. Eastern China Parasites Vect. 2015;8:162\u20138.","journal-title":"Eastern China Parasites Vect"},{"issue":"6","key":"1180_CR20","doi-asserted-by":"publisher","first-page":"708714","DOI":"10.1016\/j.canep.2014.09.002","volume":"38","author":"J Xi","year":"2014","unstructured":"Xi J, Su Y, Beeghly Fadiel A, et al. Association of physical activity and polymorphisms in FGFR2 and DNA methylation related genes with breast cancer risk. Cancer Epidemiol. 2014;38(6):708714.","journal-title":"Cancer Epidemiol"},{"key":"1180_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/mc.21979","volume":"52","author":"YL Cen","year":"2013","unstructured":"Cen YL, Qi ML, Li HG, et al. Associations of polymorphisms in the genes of FGFR2, FGF1, and RBFOX2 with breast cancer risk by estrogen\/progesterone receptor status. Mol Carcinog. 2013;52 Suppl 1:E52-59.","journal-title":"Mol Carcinog"},{"key":"1180_CR22","doi-asserted-by":"publisher","first-page":"18489","DOI":"10.1016\/j.gene.2013.04.064","volume":"524","author":"LY Tang","year":"2013","unstructured":"Tang LY, Chen LJ, Qi ML, et al. Effects of passive smoking on breast cancer risk in pre\/post-menopausal women as modified by polymorphisms of PARP1 and ESR1. Gene. 2013;524(2):8489.","journal-title":"Gene"},{"key":"1180_CR23","first-page":"14","volume":"12","author":"RM Zhu","year":"2017","unstructured":"Zhu RM, Lin W, Zhang W, et al. Modification effects of genetic polymorphisms in FTO, IL-6, and HSPD1 on the associations of diabetes with breast cancer risk and survival. PLoS ONE. 2017;12:14.","journal-title":"PLoS ONE"},{"issue":"1","key":"1180_CR24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13148-022-01363-y","volume":"14","author":"M Zhou","year":"2022","unstructured":"Zhou M, Yan JQ, Chen QX, et al. Association of H3K9me3 with breast cancer prognosis by estrogen receptor status. Clin Epigenetics. 2022;14(1):135.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"1180_CR25","doi-asserted-by":"publisher","first-page":"2343593","DOI":"10.1080\/15592294.2024.2343593","volume":"19","author":"CK Xiao","year":"2024","unstructured":"Xiao CK, Ren Y, Chen Q, et al. H4K20me3, H3K4me2 and H3K9me2 mediate the effect of ER on prognosis in breast cancer. Epigenetics. 2024;19(1):2343593.","journal-title":"Epigenetics"},{"issue":"6","key":"1180_CR26","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s00428-023-03534-5","volume":"482","author":"B Wang","year":"2023","unstructured":"Wang B, Zhou M, Shi YY, et al. Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients. Virchows Arch Int J Pathol. 2023;482(6):1047\u20131056.","journal-title":"Virchows Arch Int J Pathol"},{"issue":"9","key":"1180_CR27","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s10147-023-02378-y","volume":"28","author":"B Wang","year":"2023","unstructured":"Wang B, Zhou M, Gan XL, et al. Combined low levels of H4K16ac and H4K20me3 predicts poor prognosis in breast cancer. Int J Clin Oncol. 2023;28(9):1147\u20131157.","journal-title":"Int J Clin Oncol"},{"key":"1180_CR28","doi-asserted-by":"publisher","first-page":"8085","DOI":"10.1016\/j.cca.2014.08.014","volume":"438","author":"XL Wei","year":"2015","unstructured":"Wei XL, He JR, Cen YL, et al. Modified effect of urinary cadmium on breast cancer risk by selenium. Clin Chim Acta Int J Clin Chem. 2015;438:8085.","journal-title":"Clin Chim Acta Int J Clin Chem"},{"issue":"3","key":"1180_CR29","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1080\/01635581.2012.654586","volume":"64","author":"LY Tang","year":"2012","unstructured":"Tang LY, Su Y, He JR, et al. Urinary titanium and vanadium and breast cancer: a case-control study. Nutr Cancer. 2012;64(3):368\u2013376.","journal-title":"Nutr Cancer"},{"issue":"22","key":"1180_CR30","doi-asserted-by":"publisher","first-page":"9785","DOI":"10.7314\/APJCP.2014.15.22.9785","volume":"15","author":"YC Qin","year":"2014","unstructured":"Qin YC, Tang LY, Su Y, et al. Association of urinary cesium with breast cancer risk. Asian Pac J Cancer Prev APJCP. 2014;15(22):9785\u20139790.","journal-title":"Asian Pac J Cancer Prev APJCP"},{"issue":"5","key":"1180_CR31","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/aje\/kwv085","volume":"182","author":"SC Larsson","year":"2022","unstructured":"Larsson SC, Orsini N, Wolk A. Urinary cadmium concentration and risk of breast cancer: a systematic review and dose-response meta-analysis. Am J Epidemiol. 2015;182(5):375\u2013380.","journal-title":"Am J Epidemiol"},{"issue":"12","key":"1180_CR32","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1007\/s12011-021-02574-9","volume":"199","author":"X Zhu","year":"2021","unstructured":"Zhu X, Pan D, Wang N, et al. Relationship Between Selenium in Human Tissues and Breast Cancer: a Meta-analysis Based on Case-Control Studies. Biol Trace Elem Res. 2021;199(12):4439\u20134446.","journal-title":"Biol Trace Elem Res"},{"issue":"59","key":"1180_CR33","doi-asserted-by":"publisher","first-page":"89002","DOI":"10.1007\/s11356-022-21067-3","volume":"29","author":"B Gamboa-Loira","year":"2022","unstructured":"Gamboa-Loira B, M\u00e9rida-Ortega \u00c1, Rothenberg SJ, et al. Metal exposure and breast cancer among Northern Mexican women: assessment of genetic susceptibility. Environ Sci Pollut Res Int. 2022;29(59):89002\u201389013.","journal-title":"Environ Sci Pollut Res Int"},{"issue":"1","key":"1180_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/cam4.2707","volume":"9","author":"JY Zhang","year":"2020","unstructured":"Zhang JY, Wang MX, Wang X, et al. Associations of reproductive factors with breast cancer prognosis and the modifying effects of menopausal status. Cancer Med. 2020;9(1):385\u2013393.","journal-title":"Cancer Med"},{"issue":"3","key":"1180_CR35","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10549-022-06592-6","volume":"193","author":"YX Zhang","year":"2022","unstructured":"Zhang YX, Liang ZZ, Li YQ, et al. Association between weight change and breast cancer prognosis. Breast Cancer Res Treat. 2022;193(3):677\u2013684.","journal-title":"Breast Cancer Res Treat"},{"key":"1180_CR36","doi-asserted-by":"crossref","unstructured":"Liang ZZ, Zhang YX, Lin Y, et al. Joint effects of multiple sleep characteristics on breast cancer progression by menopausal status. Sleep Med. 2019;54:153\u2013158.","DOI":"10.1016\/j.sleep.2018.10.025"},{"key":"1180_CR37","doi-asserted-by":"crossref","unstructured":"Zhang JY, Liao YH, Lin Y, et al. Effects of tea consumption and the interactions with lipids on breast cancer survival. Breast Cancer Res Treat. 2019;176(3):679\u2013686.","DOI":"10.1007\/s10549-019-05253-5"},{"key":"1180_CR38","doi-asserted-by":"crossref","unstructured":"Ye HM, Lu MJ, Liu Q, et al. Beneficial Effect of Toxoplasma gondii Infection on the Prognosis of Breast Cancer Was Modified by Cytokines. Clin Epidemiol. 2023;15:469\u2013481.","DOI":"10.2147\/CLEP.S408182"},{"key":"1180_CR39","doi-asserted-by":"crossref","unstructured":"Chen M, Yang P. Toxoplasma gondii gra5 deletion mutant protects hosts against Toxoplasma gondii infection and breast tumors. Front Immunol. 2023 Jun 23;14:1173379.\u00a0","DOI":"10.3389\/fimmu.2023.1173379"},{"key":"1180_CR40","doi-asserted-by":"crossref","unstructured":"Arias-Calvachi C, Blanco R, Calaf GM, et al. Epstein-Barr Virus Association with Breast Cancer: Evidence and Perspectives. Biology. 2022;11(6):799.","DOI":"10.3390\/biology11060799"}],"container-title":["European Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-024-01180-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10654-024-01180-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10654-024-01180-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T06:09:21Z","timestamp":1735279761000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10654-024-01180-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1007\/s10654-024-01180-y","relation":{},"ISSN":["0393-2990","1573-7284"],"issn-type":[{"value":"0393-2990","type":"print"},{"value":"1573-7284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Guangzhou Medical Ethics Committee of the Chinese Medical Association approved the Guangzhou Breast Cancer Study (ID: 2012-8). All participants provided written, informed consent before participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}